Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25600531 | 0.89 | CHRM1 (0.38) | HRH3L3MBTL3L3MBTL1MEN1LMNA | |
| SCHEMBL25600528 | 0.86 | HRH3 (0.37) | HRH3CHRM1OPRM1OPRK1OPRL1 | |
| SCHEMBL25600532 | 0.83 | CYP3A4 (0.35) | HRH3L3MBTL3L3MBTL1MEN1KMT2A | |
| SCHEMBL25600527 | 0.81 | OPRL1 (0.38) | HRH3L3MBTL3L3MBTL1LMNACHRM1 | |
| SCHEMBL25605729 | 0.79 | HRH3 (0.36) | HRH3L3MBTL3L3MBTL1MEN1LMNA | |
| SCHEMBL25600526 | 0.78 | OPRL1 (0.34) | HRH3CHRM1OPRM1OPRK1OPRL1 | |
| SCHEMBL25600327 | 0.78 | OPRL1 (0.36) | HRH3CHRM1OPRM1OPRK1OPRL1 | |
| SCHEMBL25600508 | 0.78 | HRH3 (0.34) | HRH3L3MBTL3L3MBTL1CHRM1OPRM1 | |
| SCHEMBL25605724 | 0.77 | CHRM4 (0.39) | HRH3MEN1LMNAKMT2ACHRM1 | |
| SCHEMBL4546656 | 0.75 | CHRM1 (0.48) | SIGMAR1L3MBTL3L3MBTL1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | HRH3 3548/4885SIGMAR1 2983/4885L3MBTL3 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.